ArticleNeuropsychopharmacology reports2026
Vortioxetine-Lurasidone Augmentation for Compulsive Scratching Behavior in Prader-Willi Syndrome: A Case Report.
Article in Neuropsychopharmacology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrader-Willi syndrome (PWS) is a rare genetic disorder frequently associated with repetitive and self-injurious behaviors such as skin picking. Effective pharmacological treatments for compulsive scratching behavior in PWS remain limited. CASE PRESENTATION: We report the case of a 19-year-old woman with PWS presenting with severe, persistent scratching behavior resulting in repeated excoriations. Escitalopram produced partial improvement but was discontinued because of sedation. Treatment was switched to vortioxetine, which reduced the frequency of scratching but did not achieve remission. Subsequent augmentation with lurasidone resulted in marked improvement, with episodes decreasing from daily occurrences to once every 1-3 months and lasting only a few minutes. The patient remained stable for 2 years without recurrence of severe symptoms.
conclusionThis case suggests that vortioxetine and lurasidone may represent a potential pharmacological option for severe scratching behavior in PWS. Further studies are needed to clarify the therapeutic role of this combination approach.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.